LogicBio Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
57
- Share Price
-
$2.07
- (As of Tuesday Closing)
LogicBio Therapeutics General Information
Description
LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.
Contact Information
- 65 Hayden Avenue
- Lexington, MA 02421
- United States
LogicBio Therapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.07 | $2.06 | $0.26 - $3.77 | $68.2M | 33M | 520K | -$0.81 |
LogicBio Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (18,777) | 30,869 | 226,542 | 112,322 |
| Revenue | 10,759 | 5,410 | 3,454 | 0 |
| EBITDA | (25,224) | (38,377) | (31,041) | (40,771) |
| Net Income | (26,544) | (40,029) | (32,621) | (40,128) |
| Total Assets | 38,601 | 62,770 | 80,640 | 55,660 |
| Total Debt | 9,978 | 13,253 | 16,065 | 10,314 |
LogicBio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
LogicBio Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
LogicBio Therapeutics Comparisons
Industry
Financing
Details
000000
000000
LogicBio Therapeutics Competitors (75)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | 000 | 00000 | 000000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000000 0000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
| 000000000 000000 | Venture Capital-Backed | Roslin, United Kingdom | 0 | 00.000 | 000000 0 | |
| 0000000 0000000000 | Formerly VC-backed | Houston, TX | 00 | 00000 | 00000000000 | 00000 |
LogicBio Therapeutics Patents
LogicBio Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021902729-A0 | Modified aav capsid polypeptides and vectors | Inactive | 25-Aug-2021 | ||
| CA-3216909-A1 | Viral vector compositions and methods of use thereof | Pending | 30-Apr-2021 | 0000000000 | |
| AU-2022264585-A1 | Viral vector compositions and methods of use thereof | Pending | 30-Apr-2021 | ||
| US-20230111556-A1 | Manufacturing and use of recombinant aav vectors | Pending | 26-Feb-2021 | 000000000 | 0 |
| AU-2022227005-A1 | Manufacturing and use of recombinant aav vectors | Pending | 26-Feb-2021 | C12N15/86 |
LogicBio Therapeutics Executive Team (14)
LogicBio Therapeutics Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Mark Kay MD | Self | Co-Founder & Board Member | 000 0000 |
| Richard Moscicki MD | LogicBio Therapeutics | Chairman & Director | 000 0000 |
LogicBio Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
LogicBio Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
LogicBio Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 22, 2020
42.69 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 452
Rank
Percentile
